Compare LUCD & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUCD | STXS |
|---|---|---|
| Founded | 2018 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.5M | 201.6M |
| IPO Year | 2021 | 2004 |
| Metric | LUCD | STXS |
|---|---|---|
| Price | $1.27 | $1.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $3.94 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 659.4K | 385.7K |
| Earning Date | 03-26-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.67 | 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | $4,346,000.00 | ★ $29,346,617.00 |
| Revenue This Year | $7.69 | $34.08 |
| Revenue Next Year | $155.47 | $35.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 79.00 | N/A |
| 52 Week Low | $0.95 | $1.54 |
| 52 Week High | $1.80 | $3.59 |
| Indicator | LUCD | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 40.44 | 33.27 |
| Support Level | $1.01 | N/A |
| Resistance Level | $1.52 | $2.52 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 14.38 | 14.05 |
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.